Drug Profile
Lorazepam controlled-release - Edgemont Pharmaceuticals
Alternative Names: Delayed sustained release lorazepam beads - Edgemont Pharmaceuticals; EDG-004; Lorazepam extended-release - Edgemont PharmaceuticalsLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Edgemont Pharmaceuticals
- Class Antiemetics; Anxiolytics; Benzodiazepinones; Hypnosedatives; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Generalised anxiety disorder
Highest Development Phases
- No development reported Generalised anxiety disorder
Most Recent Events
- 05 Apr 2017 No recent reports of development identified - Phase-III for Generalised anxiety disorder in USA (PO)
- 31 May 2016 Edgemont Pharmaceuticals completes a phase III trial for Generalised anxiety disorder in USA (PO) (NCT02305797)
- 01 Jan 2015 Phase-III trials in Generalised anxiety disorder in USA (PO) (NCT02305797)